Loading provider…
Loading provider…
Hematology & Oncology Physician in San Francisco, CA
NPI: 1265505291Primary Employer
R W Weber MD a Medical Corporation
hillphysicians.com
HQ Phone
Get MD Robert's Phone Numberphone_androidMobile
Get MD Robert's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardCA State Medical License
CA State Medical License
CA State Medical License
1991 - 2025

American Board of Internal Medicine
Hematology

American Board of Internal Medicine
Medical Oncology
Saint Louis University School Of Medicine
slu.edu
Medical School
Until 1990
Scripps Clinic/Scripps Green Hospital
Fellowship • Hematology and Medical Oncology
1994 - 1997
University of California Davis Health
Residency • Internal Medicine
1990 - 1993
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99214Established patient office or other outpatient visit, 30-39 minutes | 372 | 953 |
| 2 | 99204New patient office or other outpatient visit, 45-59 minutes | 62 | 62 |
| 3 | 99232Subsequent hospital inpatient care, typically 25 minutes per day | 44 | 148 |
| 4 | 99213Established patient office or other outpatient visit, typically 15 minutes | 38 | 74 |
| 5 | 99222Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | 30 | 32 |
GM-CSF and ipilimumab therapy in metastatic melanoma: Clinical outcomes and immunologic responses.
Authors: Edward Cha, Svetomir Markovic, Lynn Spitler
Publication Date: 2015-07-24
Merkel cell carcinoma: review of 22 cases with surgical, pathologic, and therapeutic considerations.
Authors: Hubert Greenway, Michael Kosty, Cora Humberson, Vincent Massullo
Journal: Cancer
Phase II trial of nab-paclitaxel and bevacizumab as first-line therapy in patients with unresectable melanoma.
Authors: Peter Boasberg, Omid Hamid
Publication Date: 2011-05
Lead Sponsor: Effector Therapeutics
Intervention / Treatment: DRUG: Tomivosertib (eFT-508)
Lead Sponsor: Effector Therapeutics
Collaborators: Medpace, Inc., ICON plc
Intervention / Treatment: BIOLOGICAL: Pembrolizumab, DRUG: Pemetrexed, DRUG: Tomivosertib
Lead Sponsor: Celldex Therapeutics
Intervention / Treatment: DRUG: glembatumumab vedotin, DRUG: glembatumumab vedotin and varlilumab, DRUG: glembatumumab vedotin and PD-1 targeted checkpoint inhibitor (nivolumab OR pembrolizumab), DRUG: glembatumumab vedotin and CDX-301